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Lise Bjørkhaug,13 Pål Rasmus Njølstad,2,7,18,* and Anna L. Gloyn1,10,12,14,18SummaryExome sequencing in diabetes presents a diagnostic challenge because depending on frequency, functional impact, and genomic and envi-
ronmental contexts, HNF1A variants can cause maturity-onset diabetes of the young (MODY), increase type 2 diabetes risk, or be benign.
A correct diagnosis matters as it informs on treatment, progression, and family risk. We describe a multi-dimensional functional dataset of
73 HNF1A missense variants identified in exomes of 12,940 individuals. Our aim was to develop an analytical framework for stratifying
variants along the HNF1A phenotypic continuum to facilitate diagnostic interpretation. HNF1A variant function was determined by
four different molecular assays. Structure of the multi-dimensional dataset was explored using principal component analysis, k-means,
and hierarchical clustering. Weights for tissue-specific isoform expression and functional domain were integrated. Functionally annotated
variant subgroups were used to re-evaluate genetic diagnoses in nationalMODYdiagnostic registries.HNF1A variants demonstrated a range
of behaviors across the assays. The structure of the multi-parametric data was shaped primarily by transactivation. Using unsupervised
learningmethods, we obtainedhigh-resolution functional clusters of the variants that separated known causalMODYvariants frombenign
and type 2 diabetes risk variants and led to reclassification of 4% and 9% of HNF1A variants identified in the UK and Norway MODY diag-
nostic registries, respectively. Our proof-of-principle analyses facilitated informative stratification of HNF1A variants along the continuum,
allowing improved evaluation of clinical significance, management, and precision medicine in diabetes clinics. Transcriptional activity
appears a superior readout supporting pursuit of transactivation-centric experimental designs for high-throughput functional screens.Introduction
Precision medicine increasingly relies on an accurate inter-
pretation of the consequence of genetic variation. Large-
scale multi-ethnic genetic sequencing studies have chal-
lenged our understanding of the relationship between
coding variants inMendelian disease genes, including those
involved in monogenic forms of diabetes such as HNF1A
(MIM: 142410). Until relatively recently, the consensus
has been that heterozygous highly penetrant loss-of-func-
tion alleles inHNF1A give rise to a clinically distinct diabetes
subtype, characterized by an early age of onset (typically <
25 years), dominant inheritance, sensitivity to sulphonylur-
eas, and non-obesity, and termed HNF1A maturity-onset
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set ofHNF1Avariant carriers, it represents one endof abroad
spectrum of HNF1A variant effects.2–4
Genome-wide association and next-generation se-
quencing studies of randomly ascertained individuals
have challengedbinary assumptions andoverinflatedpath-
ogenicity estimates regarding variants inHNF1A (and other
Mendelian disease genes) and identified common coding
variants of low effect associated with increased risk
of type 2 diabetes (MIM: 125853).5–8 Whole-exome
sequencing studies in populations of Mexican American
ancestry have revealed a low-frequency missense variant
(c.1522G>A [p.Glu508Lys]) in HNF1A associated with a 5-
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of the phenotypic manifestation of HNF1A gene variants:
some alleles are sufficient for early-onset sulfonylurea-
responsive diabetes (HNF1A-MODY), although it should
be noted that not all carriers of these alleles get early-onset
diabetes; not even diabetes at all. Moreover, some alleles
modify susceptibility for developing complex multifacto-
rial hyperglycemia later in life (type 2 diabetes), and most
alleles will likely manifest as benign and neutral.
A correct diabetes diagnosis is important because amuta-
tion inHNF1A leads to clinical actions involving diagnosis,
treatment, and genetic counselling. Individuals with rare,
deleterious HNF1A alleles and young-onset diabetes (typi-
cally < 25 years) are sensitive to treatment with oral sulfo-
nylureas and can often avoid insulin injections until late in
life.9,10
The ubiquity of genetic sequencing means that more
novel and incidentally detected variants of uncertain clin-
ical significance (VUS) will be identified in individuals with
less extreme phenotypes.11 The challenge today is in the
ability to map HNF1A sequence-function relationships at
high fidelity, using clinical and molecular characterization
and analytical pipelines with sensitivity to capture the sub-
tleties along the pathophysiological continuum. Rigorous
functional follow-up of rare sequence-identified alleles in
HNF1A is crucial to making correct assignments of patho-
genicity. Indeed, functional data are considered a strong
line of evidence for accurate clinical diagnostic classifica-
tion of variants.12 Furthermore, it has been shown that dia-
betes severity in HNF1A variant carriers is influenced by
allele position in the gene: the transactivation domain is
more tolerant to genetic variation and variants in the latter
exons8–10 are only present in hepatocyte-dominant iso-
forms and would thus not likely translate to a strong
beta-cell phenotype.13,14
To understand the relationship between HNF1A
sequence variation, molecular dysfunction, and clinical
phenotype, we characterized the functional impact of a to-
tal of 73 HNF1A missense variants detected in the exomes
of 12,940 multi-ethnic type 2 diabetes case subjects and
control subjects using standard functional assays. Our
primary objective was to develop an analytical approach
that would enable (1) an unbiased and comprehensive
evaluation of HNF1A variant behavior based on multiple
molecular mechanisms and (2) sensitive mapping of
multi-dimensional in vitro function to HNF1A glycemic
phenotypes in vivo. We hypothesized that severity of mo-
lecular dysfunction in vitro (wild-type/wild-type-like, mod-
erate/intermediate impact, loss-of-function/deleterious)
would correlate positively with the severity of clinical
phenotype (benign, increased type 2 diabetes risk,
young-onset sulfonylurea-responsive hyperglycemia).Material and Methods
The study was approved by the regional ethical committee in Ber-
gen (#2009/2079). We investigated the function of all rare (MAF<The America0.5%) and low-frequency (0.5% < MAF < . 5%) as well as three
common (MAF > 5%) HNF1A nonsynonymous missense variants
(n ¼ 73) identified in an exome sequencing study of 12,940 type 2
diabetes case subjects and control subjects from five different
ancestry groups15 (Figure S1, Table S1). Collectively, the variants
did not enrich for a type 2 diabetes phenotype under any of the
several variant filters used (MAF < 0.1%, conserved and predicted
damaging [PolyPhen: SKAT p value ¼ 0.30, BURDEN p value ¼
0.37]).15
Bioinformatic Prediction
The following four in silico tools were used to evaluate the patho-
genicity of the alleles: SIFT,16 PolyPhen-2,17 MutationTaster,18 and
Combined Annotation Dependent Depletion (CADD).19 A CADD
cut-off score of 15 was used (>15, pathogenic).
Functional Characterization
The individual effects of the 73 HNF1A missense variants were
functionally investigated by two research teams at the Universities
of Oxford (UK) and Bergen (Norway) using four different molecu-
lar assays (see detailed description of assays below). Using two lab-
oratories allowed us to evaluate the robustness of the functional
studies. Each laboratory assessed a unique set of exome-detected
variants (n > 30), a shared subset of exome-detected variants
(n ¼ 5), shared type 2 diabetes risk variants (n ¼ 2), as well as
shared HNF1A-MODY reference variants (positive controls,
n ¼ 6) (Figures S2 and S3). The positive controls were selected
on the basis of previously reported functional data supporting
pathogenicity, clinical evidence for causality (sulfonyurea sensi-
tivity in multiple carriers), and/or genetic (co-segregation) evi-
dence to support their role pathogenesis (Table S2). Plasmid and
HNF-1A variant constructs, transactivation assays, HNF-1A pro-
tein abundance, subcellular localization, and DNA binding are
detailed below.
Plasmid and HNF-1A Variant Constructs
A construct encoding the human HNF1A cDNA (GenBank:
NM_000545.6) in cDNA3.1 His/C plasmid was used as wild-type
and template for introducing HNF1A variants using the
QuikChange XL Site-directed Mutagenesis Kit (Stratagene). The
wild-type sequence used in this study also harbors the common
coding variant c.79A>C (p.Ile27Leu) (MAF ¼ 34.8%) and a com-
mon synonymous variant c.51C>G (p.Leu17¼) (MAF ¼ 46.5%).
All constructs were verified by DNA Sanger sequencing.
For transactivation experiments, two reporter constructs were
used: (1) pGL3-RA, containing the promoter of the rat albumin
gene (nucleotide 170 to þ5) next to the Firefly luciferase gene
in vector pGL3-Basic (Promega) (kindly provided by Prof. Graeme
I. Bell, University of Chicago, Chicago, IL, USA) and (2) pGL3-
HNF4AP2, which contains the human HNF4A (MIM: 600281) P2
promoter (nucleotide 418 to þ13) next to the Firefly luciferase
gene (kindly provided by Prof. Maria Angeles Navas, Madrid Uni-
versity, Madrid, Spain). The pRL-SV40 reporter vector containing
the Renilla luciferase gene was used as internal control in the trans-
activation assay (Promega).
Transactivation Assays
Assessment of variant effects on transcriptional activity (TA) were
performed in the HeLa cell line, representing cells negative for
endogenous HNF-1A expression, and in the INS-1 (rat insulinoma
cell line), representing cells positive for HNF-1A expression.n Journal of Human Genetics 107, 670–682, October 1, 2020 671
HeLa20 and INS-1 cells21 were grown as previously described. Tran-
sient transfection of variant plasmids (wild-type or variant
HNF1A), reporter, and control plasmids was performed using Lip-
ofectamine 2000 (Life Technology), as reported.2 Luciferase activ-
ity was measured 24 h post-transfection with the Dual-Luciferase
Assay System (Promega) in a Chameleon luminometer (Hidex)
or using the Enspire platform (Perkin Elmer). Luciferase activity
was normalized for transfection efficiency by the Renilla luciferase
activity. The Bergen dataset included some variants previously
reported (p.Ile27Leu, c.92G>A [p.Gly31Asp], c.142G>A
[p.Glu48Lys], c.290C>T [p.Ala97Val], c.293C>T [p.Ala98Val],
c.298C>A [p.Gln100Lys], c.341G>A [p.Arg114His], c.392G>A
[p.Arg131Gln], c.965A>G [p.Tyr322Cys], c.1165T>G [p.
Leu389Val], c.1405C>T [p.His469Tyr], c.1460G>A [p.Ser487Asn],
c.1469T>C [p.Met490Thr], c.1541A>G [p.His514Arg], c.1544C>
A [p.Thr515Lys], and c.1729C>G [p.His577Asp]).2HNF-1A Protein Abundance
The level of wild-type and individual HNF-1A variant protein ex-
pressions in total HeLa cell lysates was determined. For this pur-
pose, the team at Bergen used 20 mL of HeLa cell lysates generated
for transactivation assays as previously described.2 HNF-1A and
actin protein levels were quantified by densitometric analysis us-
ing Quantity One 1-D software (Bio-Rad). The team at Oxford eval-
uated protein expression by transfecting HeLa cells with 5 mg of
wild-type or variants plasmids after culturing for 24 h. Total pro-
tein quantification was carried out using Bradford reagent (Bio-
Rad) and 10 mg of total protein was electrophoresed then immuno-
blotted with antibodies for HNF-1A (Santa Cruz Biotechnology)
and beta-tubulin (Santa Cruz Biotechnology) and visualized using
the ChemiDoc Imaging System (Bio-Rad). Densitometry (for west-
ern blots and EMSA) was carried out using Image Lab Software
(Bio-Rad).Subcellular Localization
For nuclear translocation assessments, the teams at Bergen and
Oxford examined HNF-1A presence in nuclear versus cytosolic
HeLa cell fractions. Cultured and plated cells were transiently
transfected with wild-type or HNF1A variant plasmids. Sequential
cell fractionation from each transfected sample was performed
24 h post-transfection as described.22 20 mg total protein from
each isolated compartment (nucleus and cytosol) was analyzed
by SDS-PAGE and immunoblotting using an HNF-1A-specific anti-
body (Cell Signaling or Santa Cruz Biotechnology, respective to
the two centers). GAPDH antibody (Santa Cruz Biotechnology)
and Topoisomerase II-alpha antibody (Cell) were used as loading
control for cytosol and nuclear compartments, respectively. The
HNF1A variant c.589_615del (p.Leu197_Leu205del), denoted
p.delB, was included as a positive control for impaired nuclear
localization (cytosolic retention).23DNA Binding
DNA binding ability test was conducted for HNF1A variants that
were located in DNA binding domain (1–287 aa), and those that
demonstrated transactivation activity < 50%. At Bergen the
HNF-1A proteins were expressed using an in vitro transcription
and translation system (TNT Coupled Reticulocyte Lysate System,
Promega) and equal amounts of synthesized protein were bound
to a [g-32P]-radiolabeled rat albumin oligonucleotide as
described.24 DNA-protein bound complexes were separated by
6% DNA retardation gel electrophoresis (EMSA) (Life Technolo-672 The American Journal of Human Genetics 107, 670–682, Octobegies) followed by autoradiography (LAS-1000 Plus, Fujifilm Medi-
cal System). Level of DNA binding was assessed by quantification
of the intensity of HNF-1A protein-oligonucleotide complexes by
the program Image Gauge 3.12 (Fujifilm Medical Systems). The
two HNF1A-MODY control variants c.335C>T (p.Pro112Leu)
and c.608G>A (p.Arg203His) were included as positive controls
for reduced DNA binding ability.24 DNA binding data for two var-
iants p.Gln100Lys and p.Arg131Gln are the same as published pre-
viously.2 The team at Oxford used 10 mg of the cell lysate used in
the protein abundance western and a CY5 labeled probe of the
same promoter sequence as used by the Bergen team. However,
they used the Odessey Infra-Red EMSA kit (Li-Cor Inc.) to conduct
binding affinity. The percentage of HNF-1A-oligo complexes for
each variant fraction was then calculated compared to wild-type.Stratification of HNF1A Variants with Unsupervised
Learning Methods
We designed an analytical pipeline to stratify functionally charac-
terized HNF1A variants along the spectrum of glycemic pheno-
types (Figure S3). Briefly, the pipeline begins with preparation of
the dataset for analysis using unsupervised learning tools. This
was followed by the addition of two scores to each variant, one
to account for functional domain and the other for spatial varia-
tion in HNF1A isoform expression (exon location), as there are
well-established correlations between variant position in HNF1A
and clinical phenotype.13,14 The ‘‘polished’’ dataset was then pro-
cessed using principal component analysis, k-means, and hierar-
chical clustering methods (Figure S3).The prcomp (principal compo-
nents analysis) function in R (stats package v.3.5.0) was used to
perform principal component analysis. Polished data matrices
were zero centered and scaled to account for unit variance. We
used the NbClust Package in R for determining the best number
of clusters (distance measure set as ‘‘Euclidean’’) to estimate the
optimal number of k-means clusters in PC space25 (Figures S4A
and S4B). Hierarchical clustering was performed on a Euclidean
distance matrix comprised of PC scores for each allele from total
principal components that explained >85% of data variance (Fig-
ures S4C and S4D) using the hclust (hierarchical clustering) function
in R. The WARD minimum variance hierarchical clustering
method (ward.d2) was selected as it yielded highest resolution
clusters in a comparative analysis against complete, single, and
average linkage methods (data not shown) based on (1) predicted
grouping patterns of wild-type and MODY/type 2 diabetes risk
reference variants and (2) known molecular function of variants
which co-occupied clusters defined by wild-type, type 2 diabetes
risk, andMODY reference variants. To compare the cluster dendro-
grams of variants shared between Oxford and Bergen, we used the
untangle, tanglegram, and entanglement functions in R (part of
the dendextend package) to untangle dendrogram lists and find
the best alignment layout, plot the two dendrograms side by
side, and compute the quality of alignment (entanglement coeffi-
cient), respectively.Dataset Preparation for Clustering Analysis
The functional datasets were prepared for PCA and clustering
analysis by harmonizing the number of variables across tested
variants. DNA binding ability was interrogated for only a small
subset of variants, so EMSA data were excluded. Functional data
were available in three different formats: raw instrument data,
data normalized to internal assay controls (renilla luciferase for
TA assay, beta-tubulin/actin antibody for protein abundancer 1, 2020
assay, and nuclear:cytosolic ratio of raw protein abundance reads
for nuclear localization) expressed as biological replicates, and
fully processed summary data normalized to wild-type values.
The most statistically suitable input format for PCA and unsuper-
vised clustering is functional data normalized to internal assay
controls (semi-processed) as intra-assay measurements are harmo-
nized (versus raw instrument data) and the organic structure of
the data is retained and uninfluenced by assumptions (versus
wild-type normalized data). Further, this format yielded the
most robust clustering trends based on distribution quality in
multivariate space and known and expected sequence-function
relationships. Scores for tissue-specific expression of HNF1A iso-
forms (implications for clinical phenotypic manifestation) and
functional domain (varied levels of mutation tolerance) were as-
signed to each variant (Table S3). For stratification of HNF1A var-
iants with unsupervised learning methods, see Figure S4 and
Material and Methods.
Variant-Phenotype Mapping
We surveyed the UKMODY Diagnostic Registry (Royal Devon and
Exeter NHS Foundation Trust, Exeter, UK) and the Norwegian
MODY Registry (Haukeland University Hospital, Bergen, Norway)
for functionally annotated HNF1A missense variants. A total of
162 and 53 HNF1A missense variants were documented in the
UK and Norwegian diagnostic registries, respectively. Tables S4
and S5 show the list of clinical features that were available from
the database for alleles which overlapped with the Oxford-Bergen
dataset (not all features available for each variant). Sequence vari-
ants in the Norwegian MODY Registry were classified prior to the
incorporation of the ACMG/AMP guidelines,12 as described26 us-
ing a 5-tier score system.27 Sequence variants in the Exeter
MODY Registry had been classified using the ACGS guidelines
from 2013 (see Web Resources), a 5-tier system used in the UK
prior to the advent of the ExAC database and publication of the
ACMG/AMP guidelines.12 Original clinical reports of carriers
were accessed for additional details, particularly where clinical fea-
tures were sparse—such as extra-pancreatic features, vascular com-
plications, additional family history data, and whether, for
example, other MODY genes were next-generation sequenced as
part of a MODY gene panel.28 The classification system adopted
by each center was used for reclassification of variants from its
database.
Role of the Funding Source
The funders of the study had no role in study design, data collec-
tion, data analysis, data interpretation, or writing of the report.
The corresponding author had full access to all the data in the
study and had final responsibility for the decision to submit for
publication.Results
In Silico and In Vitro Functional Characterization of
Variants
To resolve HNF1A genotype-phenotype complexity, we
sought to evaluate the function of 73 HNF1A missense al-
leles which were observed almost 26K times in the exomes
of 13K multi-ethnic type 2 diabetes case subjects and
control subjects. The majority of HNF1A variants were
identified in both type 2 diabetes case subjects and controlThe Americasubjects, and for the few observed exclusively in type 2 dia-
betes case subjects, they were identified with a frequency
of either one or two case subjects per variant (Table S1).
Although there was no evidence for HNF1A association
with type 2 diabetes susceptibility in the study either at
the single variant or at the gene level, there was a marginal
aggregate association with type 2 diabetes risk in a multi-
gene test (p ¼ 0.023) which included rare coding alleles
in a set of genes implicated in monogenic/syndromic dia-
betes or related glycemic traits.15 Consensus across multi-
ple in silico tools for predicting pathogenicity was observed
in only 38 of the 73 variants (53%) (Table S1). Based on
CADD scores (suggested pathogenicity cut-off > 15),
70% of the missense variants would be bioinformatically
classified as disease causing (i.e., sufficient to cause
MODY).19
The 73 HNF1A variants were divided between the two
centers (Oxford and Bergen) and individually evaluated
in terms of functional effect using a common pipeline
including assays measuring variant effect on HNF-1A
transcriptional activity, subcellular localization, protein
expression level, and DNA binding ability (Figures S1–
S3). The Oxford laboratory investigated variants pre-
dominantly of South-East Asian etiology, while the Ber-
gen laboratory studied variants mainly of European
etiology.
The variants demonstrated a wide range of functional ef-
fects from benign to damaging across assays and labora-
tories with highest variability in transactivation assess-
ments, particularly through regulation of the rat albumin
promoter in HeLa cells (activity range 30%–110% in
Bergen data [Figure S5A], 52%–114% in Oxford data
[Figure S6A]). Transcriptional activity was consistently
higher for variants usingHNF4A P2 promoter in INS-1 cells
(versus rat albumin promoter in HeLa cells) (activity range
40%–90% Bergen data, 77%–158% Oxford data), and most
likely due to interference of endogenous HNF-1A in INS-1
cells (2- to 4-fold higher basal promoter activity, Figures
S5B and S6B). In assessments of protein abundance,
>85% of all variants displayed adequate HNF-1A protein
levels (>60%, Figures S5C and S6C). Similarly, in nuclear
translocation assays, most variants were predominantly
detected in the nucleus (level > 60%), the exception being
five variants from the Bergen dataset (c.827C>A
[p.Ala276Asp], p.Ser487Asn, c.1812C>G [p.Ser604Arg],
c.1322C>A [p.Thr441Lys], p.Arg131Gln) (Figures S5D
and S6D) from the Oxford dataset (c.185A>G
[p.Asn62Ser], c.1552C>T [p.Leu518Phe], c.1605C>A
[p.Ser535Arg], c.1610C>T [p.Thr537Met], c.1748C>A
[p.Arg583Gln]) displaying < 50% level. The subsets
of variants investigated by EMSA demonstrated overall
normal DNA binding ability (95% of variants > 60%),
with the exception of one variant from the Bergen
dataset (p.Arg131Gln < 50%) and five from Oxford
dataset (p.Asn62Ser, c.340C>T [p.Arg114Cys], c.467C>T
[p.Thr156Met], c.481G>A [p.Ala161Thr], p.Ser535Arg <
50%) (Figures S5E and S6E).n Journal of Human Genetics 107, 670–682, October 1, 2020 673
Figure 1. Eigendecomposition of Principal
Components Explaining > 85% of Variance
Shown are (A) Oxford and (B) Bergen data-
sets. TA INS1_P2 and TA HeLa_ALB are tran-
scriptional activity data from INS-1 cells
using HNF4A P2 promoter and from HeLa
cells using rat albumin promoter, respec-
tively. PE, protein expression; nuc loc, nu-
clear localization data.Multi-Dimensional Data Analysis
We performed unsupervised stratification of the HNF1A
variants using the multi-dimensional in vitro functional
data (semi-processed data normalized to internal technical
controls in each assay) supplemented with scores for iso-
form expression and functional domain, with the aim of
mapping molecular dysfunction to clinical phenotype.
Each of the two datasets were analyzed independently to
minimize the interference of inter-laboratory variability
with true biological signal. We used principal component
analysis to facilitate informative dissection and visualiza-
tion of multi-parametric functional data. Eigendecomposi-
tion of the datamatrices revealed transcriptional activity as
the greatest contributor to data variance and structure
(Figure 1). To enable variant subgroup discovery for func-
tion-phenotype mapping, data were partitioned using (1)
k-means clustering in PC space (Figure 2) and (2) hierarchi-
cal clustering using data coordinates from the total num-
ber of informative principal components for each dataset
(Figure 3). The analysis yielded variant clusters neatly orga-
nized along the spectrum ofHNF1Amolecular dysfunction
ranging from neutral/benign to intermediate to damaging.
As such, we broadly annotated the known HNF1A in vivo
spectrum, from benign to type 2 diabetes risk-modifying
to HNF1A-MODY (inherited early-onset hyperglycemia,
likely to be sulfonylurea-responsive based on MODY regis-
try data), onto the principal components plots and den-
drograms based on the spatial distribution of the variants
along the in vitro data-derived functional spectrum, from
wild-type/wild-type-like to intermediate to damaging (Fig-
ures 2 and 3). To understand (mis)alignment ofHNF1A var-
iants shared between the two centers, we visually
compared the cluster dendrograms of shared variants
only (Figure S7). We computed an entanglement coeffi-
cient (the quality of the alignment of the two dendrograms
expressed as a value from 0 to 1 where lower values corre-
spond to higher quality alignment) of 0.055 which indi-
cated good high-quality alignment of shared variants
(Figure S7).674 The American Journal of Human Genetics 107, 670–682, October 1, 2020Clinical Interpretation of HNF1A
Variants
To assess the medical diagnostic utility
of multi-tiered HNF1A sequence-func-
tion annotations, we examined their
mapability to HNF1A clinical pheno-
type using clinical data from overlap-
ping HNF1A missense variants in theUK and Norway MODY diagnostic registries (Tables S4
and S5).
Of the 31 total overlapping variants between our func-
tional effort and the UK registry, 19 were originally classi-
fied as pathogenic/likely pathogenic and 15 as VUS/likely
benign in the diagnostic registry. Three of the 31 overlap-
ping variants (c.1816G>A [p.Gly606Ser], p.His469Tyr,
c.871C>T [p.Pro291Ser]) were present under both patho-
genic/likely pathogenic (where they were considered the
MODY-causal variant in the case subjects) and VUS/likely
benign (cases of co-occurrence with a pathogenic variant
in HNF1A or another MODY gene) original clinical classifi-
cations. All 15 missense variants categorized as VUS/likely
benign in the UK database demonstrated benign clustering
patterns in our analysis (i.e., did not form subgroups
with variants which exhibited impaired function). How-
ever, for 10 of the 19 variants clinically categorized as
pathogenic/likely pathogenic in the UK diagnostic data-
base (p.Ala161Thr, c.521C>T [p.Ala174Val], c.139G>C
[p.Gly47Arg], p.Gly606Ser, p.His469Tyr, c.1235T>C
[p.Met412Thr], p.Asn62Ser, p.Pro291Ser, p.Arg131Gln,
c.29C>T [p.Thr10Met]), patterns of in vitro functional clus-
tering patterns did not match clinical diagnostic variant
interpretation. The variants co-occupied clusters either
with known type 2 diabetes risk modifiers (some moder-
ately impacted in functional assays) or with wild-type/
neutral variants. Discordance between functional geno-
type and clinical variant interpretation prompted a thor-
ough reassessment of variant pathogenicity.
The missense variant p.Asn62Ser (gnomAD allele count
n ¼ 33) was consistently dissimilar to dysfunctional vari-
ants in dendrograms and k-means derived clusters from
both Bergen and Oxford datasets (Figures 2 and 3). In the
UK MODY registry, it was identified in an obese individual
whowas diagnosed with diabetes at age 36 years (Table S6).
The patient suffered from microvascular complications
(MIM: 603933) (nephropathy and retinopathy) (Table
S6). These features are inconsistent with neither HNF1A-
MODY nor a type 2 diabetes phenotype (which might be
Figure 2. K-Means Clustering
HNF1A missense alleles characterized at Ox-
ford (A) and Bergen (B) in principal compo-
nent (PC) space. Blue and green k clusters
represent alleles with benign and benign-
to-intermediate effects on function, respec-
tively; purple k clusters represent alleles
with intermediate functional impact; red k
clusters indicate intermediate-to-damaging
or functionally damaging alleles.familial considering the number of affected individuals in
the carrier’s pedigree). HNF1A was the only MODY gene
sequenced in this individual as genetic testing was per-
formed before the advent of the targeted MODY gene
exome sequencing panel which is the current diagnostic
procedure. Alone, p.Asn62Ser allele frequency values are
sufficient to confidently re-categorize the variant as VUS/
likely benign in the context of MODY (Figure 4).
The variants p.Ala174Val and p.Pro291Ser, characterized
by both laboratories, weremore difficult to interpret. In the
Oxford dataset, these variants formed a separate outlying
k-means-derived cluster (Figure 2). They also occupied an
independent subgroup in hierarchical clustering whichThe American Journal of Human Gbranches high on the height scale
away from the larger cluster defined
by wild-type and other neutral variants
(Figure 3). Atypically high luciferase re-
nilla values (internal luciferase reporter
gene assay control used for normaliza-
tion) were reported for these variants
as well as for p.Ser535Arg, which have
resulted in a potentially exaggerated
reduction in transactivation values for
these variants upon normalization to
the internal assay reference in the Ox-
ford dataset (Figure S6). In the Bergen
dataset, these variants also consistently
lie in the type 2 diabetes risk modifier
zone (not pathogenic for MODY) (Fig-
ures S2 and S4). Not only are the
activity profiles of p.Ala174Val and
p.Pro291Ser dissimilar to those of path-
ogenic MODY variants, they also occur
at a much higher frequency in the gen-
eral population (Figure 4). In terms of
clinical profiles, p.Ala174Val was de-
tected in an individual with diet-
controlled diabetes, which was diag-
nosed at age 25 years (Table S6). The
p.Pro291Ser variant was detected in an
overweight individual who was diag-
nosed with diabetes at age 42 years
when it was classified as likely patho-
genic/pathogenic (Table S6). In another
unrelated individual, p.Pro291Ser was
co-expressed with p.Gly31Asp andboth were annotated as VUS/likely benign in the diag-
nostic database.
The clinical diagnostic classifications of p.Gly606Ser and
p.Ala161Thr did notmatch clustering patterns inmultivar-
iate space (Figures 2 and 3). The variants did not impact
HNF-1A function in the in vitro assays tested. The fre-
quency associated with these variants (n ¼ 12 alleles in
gnomAD and n ¼ 2 in the Exeter diagnostic clinic) are
inconsistent with those of rare MODY-causing variants.
The p.Gly606Ser variant has also been found in a single
case of hyperinsulinemic hypoglycemia (on diazoxide
treatment; MIM: 256450) in the UK registry and in this
case was classified as VUS/likely benign.enetics 107, 670–682, October 1, 2020 675
Figure 3. Hierarchical Clustering Analysis
HNF1Amissense alleles characterized at Ox-
ford (A) and Bergen (B). WARD minimum
variance method was used and analysis per-
formed using orthogonally transformed
functional data from PC1-PC4 (>85% ex-
plained variance) from Oxford dataset and
PC1-PC5 (>85% explained variance) form
Bergen dataset. To optimize visualization
of the function phenotype gradient, some
branches were rotated. The numbers of
the y axes of (A) and (B) refer to clustering
height calculated as by Ward’s criterion
(total within-cluster variance).In clustering analysis, p.His469Tyr occupied either the
same or highly similar (adjacent) subgroups as wild-type
(Leu27 and Ile27) (Figure 3). The clinical features of the
variant carrier described in Table S6 are consistent with se-
vere young-onset familial diabetes; however, the allele
high frequency in gnomAD is 32. Another variant in
HNF1A, c.620G>A (p.Gly207Asp) (not present in gno-
mAD), was, however, detected in the same individual. It
was identified in three other case subjects (including co-
occurrence with p.His469Tyr) and was classified as patho-
genic/likely pathogenic each time it was identified in the
UK MODY Registry. Thus, it is likely that p.Gly207Asp is
the MODY-causal variant and that p.His469Tyr is either
benign or potentially type 2 diabetes risk-modifying.
Despite alignment between clustering pattern and
clinical diagnostic interpretation (Figures 2 and 3),
c.1576G>A (p.Asp526Asn) was reclassified from patho-
genic/likely pathogenic to VUS/likely benign. In transacti-
vation assays, HNF1A-p.Asp526Asn was the most impaired
of all tested exome-identified variants in the Oxford data-
set (50% in HeLa and 80% in INS-1 cells; MODY refer-
ence variants exhibited transactivation range of 20%–676 The American Journal of Human Genetics 107, 670–682, October 1, 202040% in HeLa cells and 30%–50% in
INS-1 cells in Oxford, with the excep-
tion of p.Arg203His and c.347C>T
[p.Ala116Val], which yielded transacti-
vation values of 40% and 60% in
HeLa and 50 and 100% in INS-1 as-
says, respectively). The variant is
observed only five times in gnomAD,
which suggests it might not be causal
for MODY (Figure 4). The clinical pro-
file of the p.Asp526Asn carrier did not
appear to be consistent with HNF1A-
MODY, besides presence of diabetes
in three generations of the carrier’s
family. The variant carrier had BMI
32.4 kg/m2 and was diagnosed with
diabetes at age 33 years. Other clinical
features included dyslipidemia (MIM:
144250), polycystic ovary syndrome
(MIM: 184700), insulin resistance
(MIM: 610549), and hypertension(MIM: 145500). The variant was also found in a patient
in the Norwegian MODY registry. This patient, diagnosed
at 19 years of age, had normal BMI and C-peptide levels.
Type 1 diabetes (MIM: 222100) autoantibody status and
type 1 diabetes risk score were not known. The carrier
was treated with metformin. His mother and the mother’s
brother also have diabetes (treated with diet and insulin,
respectively). Moreover, the patient was diagnosed with
Crohn disease (MIM: 266600). Altogether, this suggests
that the carriers might have a combination of type 2 dia-
betes and HNF1A-MODY, which is not uncommon, or a
phenotype representing a possible continuum of diabetes
sub-phenotypes from MODY to type 2 diabetes.5 Further,
the variant is expressed in the hepatocyte-dominant iso-
form and is thus unlikely to manifest in a strong beta-cell
phenotype despite its poor functionality.
Of the 19HNF1Amissense variants that overlapped with
the Norwegian MODY Registry, 18 were originally classi-
fied as benign (class 1), likely benign (class 2), or VUS (class
3), and 1 (p.Ala276Asp) as likely pathogenic (class 4) in the
diagnostic registry. The variant p.Ala276Asp consistently
demonstrated impaired HNF-1A function in in vitro assays
Figure 4. Distribution of Functionally Annotated HNF1A Missense Alleles
(A and B) As a function of frequency in the (A) UKMODY diagnostic registry and (B) NorwayMODY diagnostic registry on the x axis and
reported frequency in the genome aggregation database (gnomAD) on the y axis. Alleles are colored on the basis of the (re)classification
scheme on the top right.
(C) Frequency of functionally characterized exome-detected HNF1Amissense alleles in gnomAD. The red and orange dashed lines mark
known ultra-rare, MODYpathogenic (allele count% 2, AF< 0.0008%) and low frequency type 2 diabetes predisposing allele frequencies
(allele count % 121, AF < 0.04%) respectively.
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and clustered with the MODY reference variants in the un-
supervised clustering analyses, supporting the clinical
interpretation of this variant as pathogenic (Figures 2
and 3). It was also clinically classified as likely patho-
genic/pathogenic in the UK MODY registry (Figure 4). All
variants originally classified as benign/likely benign/VUS
(class 1–3) in the Norwegian registry clustered in the
benign or intermediate type 2 diabetes risk modifier
zones, with the exception of four variants (c.1016C>T
[p.Thr354Met], p.Thr441Lys, c.1745A>G [p.His582Arg],
c.1756G>A [p.Ala586Thr]), which demonstrated variable
trends across clustering methods (Figures 2 and 3).
In k-means clustering along principal component 1 and
principal component 2, these variants co-occupy a hard
cluster with MODY reference variants and variants which
exhibited damaging in vitro function. This is not entirely
unexpected for HNF1A-p.Thr441Lys which displayed
reduced activity (50% on both promoters in INS-1 and
HeLa cells) and with reduced (<40%) nuclear localization.
Although, in hierarchical clustering, where (dis)similarity
between variants was determined using principal compo-
nent scores from all principal components contributing
to >85% of overall variance, the trends were more consis-
tent with clinical features and classification; p.Thr441Lys
and p.Thr354Met are in the type 2 diabetes risk modifier
space of the in vivo continuum, hierarchically distanced
from the sub-cluster defined by the majority of MODY
reference variants and pathogenic damaging variants
p.Ala276Asp and c.1135C>A (p.Pro379Thr). The clinical
phenotypic data of the p.Thr354Met variant carriers seems
more consistent with type 1 diabetes. The p.Thr354Met
variant was identified in two unrelated individuals. Upon
revisiting clinical data on these two allele carriers, it was
found that one of the carriers with insulin-treated diabetes
from age 14 years was positive for GAD and IA2 autoanti-
bodies. A sister of the proband had diabetes, but the par-
ents were apparently unaffected. The other p.Thr354Met
variant carrier had autoantibody-negative diabetes from
age 12 years without strong family history of diabetes
(grandmother only). Moreover, the population frequency
(n ¼ 18 in gnomAD) associated with this variant allele is
inconsistent with rare, causal MODYalleles. Thus, the clin-
ical phenotypic data of the p.Thr354Met variant carriers
seem more consistent with type 1 diabetes. In the
p.Thr441Lys variant carrier, another variant in HNF1A
c.872dup (p.Gly292Argfs*25) was considered the patho-
genic MODY variant (Table S7). Moreover, the population
frequency values of p.Thr441Lys (gnomAD allele count n
¼ 18) and p.Thr354Met (gnomAD allele count n ¼ 7) are
slightly higher than expected for rare disease-causing vari-
ants (Figure 4). As for p.His582Arg (gnomAD allele count n
¼ 14) and p.Ala586Thr (gnomAD allele count n ¼ 20), in
hierarchical clustering, these variants form a subgroup
defined by liver isoform variants which demonstrated sub-
optimal function in one or more in vitro assays. Much like
p.Asp526Asn, these variants are likely to be strong type 2
diabetes risk modifiers. The p.His582Arg variant carrier678 The American Journal of Human Genetics 107, 670–682, Octobewas diagnosed with diabetes age 11 years, she had a BMI
of 29 at referral one year later, and C-peptide was measured
to 1,000 pmol/L (Table S7). The p.Ala586Thr variant carrier
was diagnosed at age 11, C-peptide positive (78 pmol/L),
negative GADA, IA2A, ZnT8A, with no known family his-
tory of diabetes, and treated with insulin (Table S7).
Based on this comprehensive variant re-assessment
effort, we changed the classification of 7 out of 31 vari-
ants shared with the UK MODY diagnostic database
(p.Ala161Thr, p.Ala174Val, p.Gly606Ser, p.His469Tyr,
p.Asn62Ser, Pro291Ser, p.Asp526Asn) from likely patho-
genic to VUS/likely benign (Figure 4) and all five variants
categorized as VUS (class 3) or VUS/likely benign (class
3) in the Norway MODY registry (p.Tyr322Cys,
p.Thr354Met, p.Thr441Lys, p.Asp526Asn, and p.Hi-
s582Arg) to likely benign (class 2) (Figure 4). This repre-
sents 23% and 26% of total HNF1A missense variants
in the UK and Norway MODY registries, respectively,
that overlap with the functionally interrogated HNF1A
missense variants detected in the exomes of 13K multi-
ethnic type 2 diabetes cases and controls.Discussion
In this study, we investigated the functional impact of
73 missense variants in HNF1A, detected by exome
sequencing of a multi-ethnic type 2 diabetes case-control
cohort from four different mechanistic angles (Figures S1
and S3). We developed an approach for the analysis of
multi-parametric functional data which, in the context of
HNF1A, has enabled (1) a holistic assessment of variant
behavior by combining as many mechanistic dimensions
as possible, (2) unbiased stratification along the spectrum
of glycemic phenotypes ranging from neutral/benign ef-
fects, to modification of multifactorial polygenic diabetes
risk, to deleterious and causal for early-onset sulfonylurea-
responsive diabetes, (3) an assessment of the relative
contributions of each functional parameter to molecular
variability, and (4) rigorous phenotypemapping and a thor-
ough re-evaluation of the clinical classifications of overlap-
ping variants in two national MODY diagnostic registries.
Revisiting clinical variant classifications using HNF1A
functional clusters led to the reclassification of 4% (7/
162) and 9% (5/53) of all HNF1A missense variants in
the UK and NorwegianMODY diagnostic registries, respec-
tively. Decisions on variant reclassification were primarily
motivated by the juxtaposition of allele frequency values
in the general population (based on gnomAD allele counts)
against their frequency in the MODY diagnostic registries
(highest frequency values belonged to bona fide loss-of-
function alleles used as MODY reference controls in this
study) (Figure 4). This is based on the rules given by the
ACMG guidelines for variant interpretation: ‘‘an allele fre-
quency in a control population that is greater than expected
for the disorder is considered strong support for a benign inter-
pretation for a rare Mendelian disorder’’ (BS1).12 Informationr 1, 2020
from other layers of variant annotation such as in vitro
function (in the tested assays), clinical features, family his-
tory, ethnicity, and in silico prediction all helped to support
reclassification decisions.
Dissection of the individual principal components re-
vealed transactivation to be the primary contributor to
the spatial distribution of multi-parametric data. This sug-
gests that it might be a superior functional readout and
potentially more informative than other molecular assays
for assessing HNF1A variant pathogenicity, and in line
with our previous experience on various functional assays
of HNF1A variants.2 Since transactivation is a relatively all-
encompassing measure of transcription factor protein
function, we assumed defects in transcriptional activity
would capture defects in its biochemical prerequisites (pro-
tein expression, nuclear transport, DNA binding). While
this may have been the case for the majority of function-
ally interrogated HNF1A variants, p.Arg203His and
p.Ala116Val highlight the limitations of this assumption.
For these variants, severely impaired DNA binding ability
was not adequately captured by transactivation. This
might explain clustering of p.Ala116Val and p.Arg203His
in the intermediate zones among type 2 diabetes risk mod-
ifiers, and not directly among MODY reference alleles, in
both k-means and hierarchical clustering for both centers
(Figure 3).
We were able to mitigate error associated with handling
data from two centers with methodological differences by
benchmarking several HNF-1A variants (benign, type 2 dia-
betes risk, and MODY) in both laboratories. Discrepancies
between the two centers with respect to shared variants
can be explained in part by variability in technical proto-
cols between laboratories and the handling of samples by
various individuals over the course of the study. The rela-
tive clustering position of the shared variants is impacted
by the function trends observed in each dataset; while
the majority of Oxford variants behaved wild-type-like,
the Bergen dataset was more complex as variants demon-
strated a wider range of effects. For instance, for an inter-
mediate variant and a known type 2 diabetes risk modifier
such as p.Glu508Lys, the dissimilarity to MODY reference
alleles is more pronounced in the Bergen dataset where
there are more data points between moderately impaired
and damaging function (Figure S7).
While important, informative, and powerful first lines of
evidence, functional annotations should not be treated as
superior or stand-alone determinants of variant pathoge-
nicity, which they have not in this study. Indeed, the
same variant in a MODY gene can give rise to a spectrum
of clinical phenotypes and exhibit variable penetrance de-
pending on genomic (regulatory variants in cis or trans, or
haplotype epistasis) and environmental (epigenomic)
context which are difficult to capture in functional assess-
ments.29–33 It is also entirely possible that some of the
noise in functional-clinical mapping is a reflection of the
heterogeneity in the clinical phenotypic manifestation of
HNF1A variants.5 The same variant which has a mild effectThe AmericaonHNF1A function, and thus beta-cell function and ability
to respond appropriately to a given level of glycemia, could
play out differently in individuals who are already strug-
gling to meet the insulin demand through insulin resis-
tance and/or other genetically driven defects in their
beta-cells.34Another aspect to consider is the expected vari-
ation in clinical practice between the two centers in the UK
and Norway to which diabetes patients have been referred.
It would thus be naive to attempt to draw conclusions
regarding variant effects in vivo from, for example, a single
registry observation. The reality of phenotypic variant
manifestation is often complex, context dependent, non-
linear, and spectrum based. Developing a contextual and
thorough understanding of variant behavior from diverse
functional, clinical, biochemical, and demographic data-
sets is necessary to facilitate highly accurate interpretation.
The p.Asp526Asn variant in HNF1A is a perfect example
that illustrates the need for nuanced evaluations of variant
effects despite the availability of multiple layers of func-
tional annotation from various cell systems. The variant
was clinically classified as pathogenic/likely pathogenic
and exhibited impaired in vitro functional activity (shared
a cluster with knownMODY-causal variants). Its impact on
molecular function would be consistent with biomarker
profiles (hsCRP and glycans) suggestive of HNF1A-
MODY. Yet, re-evaluation of the clinical features of variant
carriers in UK and Norway diabetes registries and the fact
that it is present only in the longest HNF1A transcript iso-
form expressed predominantly in liver suggest that it is
more likely to be a contributing factor to common multi-
factorial diabetes rather than a primary driver of early-
onset sulfonylurea-responsive familial hyperglycemia.
Integration of isoform weights into the unsupervised clus-
tering model helped separate bona fide loss-of-function
MODY variants from functional variants expressed in
exons 8–10 at the lowest level of hierarchical clustering.
The recent advent of multiplexed assays of variant ef-
fects (MAVEs) has made it possible to interrogate the func-
tion of every possible sequence perturbation in a single
experimental system.35 Successful and productive imple-
mentation of these technologies requires overcoming the
technical and analytical complexities associated with
scaling up, which represent the most significant barrier
in the face of closing the chasm between variant resolution
and variant interpretation. A meticulously designed MAVE
for HNF1A would enable functional annotation of all
possible missense variants (>12,000) in a single assay. A
high-performance variant classifier built using MAVE-
based data can then be used to generate an exhaustive
catalog of variant effects which researchers and clinicians
can consult upon sequence-identification of an HNF1A
variant.
The performance and predictive utility of any model
built using HNF1A MAVE-derived function scores would
be enhanced immeasurably upon calibration against
these multi-layered data and comprehensively annotated
function-clusters. These data can also improve existingn Journal of Human Genetics 107, 670–682, October 1, 2020 679
prediction algorithms which operate on the basis of multi-
factorial probability and multi-data integration such as
CADD (Combined Annotation-Dependent Depletion),
MutationTaster, FitCons (fitness consequence), and
VAAST (Variant Annotation, Analysis and Search Tool).
Further, they can be incorporated into rigorous and
collaborative multi-level annotation efforts led by the
Clinical Genome Resource (ClinGen) program and evi-
dence-based disease-specific variant classification data-
bases. Lastly, our approach can assist in filtering HNF1A
missense variants for gene burden testing of rare variants.
An immediate example is its application to the 50K
exomes in the UK Biobank not ascertained on the basis
of diabetes. At present, in the UK Biobank dataset, the
number of carriers of HNF1A variants that overlap with
variants functionally investigated in our effort are insuffi-
cient to conduct a robust gene burden analysis. However,
we have observed that seven variants present in the UK
biobank and predicted by our functional data to be likely
damaging (p.Asp526Asn, p.Arg171Gln, p.Thr354Met,
p.Gly288Arg, p.His582Arg, p.Pro379Thr, p.Ser592Pro)
were not identified in patients with diabetes; it is possible
that these alleles represent very rare pathogenic variants
causing MODY with reduced penetrance or are type 2 dia-
betes risk variants.
In conclusion, we have developed an analytical frame-
work for robust and unbiased variant stratification using
multi-dimensional functional follow-up data from the
largest number of exome-identified missense variants in
HNF1A ever studied. This allowed us to annotate func-
tional clusters with clinical knowledge and identify discor-
dant classifications between functional genotype and
clinical phenotype. We believe our pipeline is an impor-
tant proof-of-principle technical contribution on the
path toward more reliable, scalable, and comprehensive
mapping of sequence-function relationships: a significant
factor in making well-informed initial judgements of allele
pathogenicity in the context of individual phenotypic
presentations.Data and Code Availability
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Figure S1. Ethnic Composition of a Multi-Consortia Led Exome Sequencing Study  
(A). Molecular characterisation pipeline adopted by research groups at Oxford and Bergen to annotate the 
function of exome-detected HNF1A missense variants (B). Exome sequence data was generated from ~13K 
individuals (6,504 type 2 diabetes cases and 6,436 controls) from five ancestry groups with 82x mean 
coverage across the protein coding sequence of 18,281 genes, identifying 3.04 million variants 

























Figure S2. Division of Exome-Identified Non-Synonymous Missense Alleles in HNF1A Between 
Oxford and Bergen for Large-Scale Collaborative Functional Follow-up(A) Oxford variant set (B) 
Bergen variant set (C) Distribution of exome-detected HNF1A variants by centre based on exon position 












Figure S3. Analytical pipeline for unsupervised stratification of HNF1A missense variants along the 
in vivo glycaemic spectrum using multi-dimensional in vitro functional data. The pipeline we 
developed to perform unbiased classification of functionally characterised missense alleles in HNF1A is as 
follows: 1) dataset preparation (omitting missing values and unevenly represented functional parameters, 
and selecting the optimal input data format), 2) assignment of weights for tissue-specific isoform expression 
(liver v pancreatic beta-cell dominant isoforms) and functional domain (dimerization, undefined, DNA 
binding, transactivation), 3) Dimension reduction by principal component analysis, 4) retention of values 
from principal components which contribute the most to data variance according to Kaiser’s criterion 
(>85% explained variance by eigenvalues i.e. all PCs with standard deviation > 1) to avoid fitting noise, 5) 
hierarchical clustering analysis of data points from PCs retained in step 4 using WARD minimum variance 



















Figure S4. Assessment of the Optimal Number of Clusters to Use for Partitioning the Multi-
Dimensional Datasets. Dataset generated at (A) Oxford and (B) Bergen. Best cluster scheme obtained 
using NbClust R package which provides majority rule across 30 tested indices using euclidean distance. 














Summary of Figure S5 and S6 - Functional studies of Protein Variants  
The variants studied at both Centers included five exome variants (p.Asn62Ser, p.Ala174Val, p.Pro291Ser, 
p.Thr196Ala, p.Arg583Gln), two type 2 risk variants (p.Ala98Val, p.Glu508Lys), and six MODY variants 
(super controls; p.Ala116Val, p.Arg203His, p.Pro112Leu, p.Pro447Leu, p.Thr260Met, p.Pro519Leu), with 
single variants missing in some individual assays. 
Correlation of functional effects between centers - For the transactivation assay, testing two promoters in 
different cell lines (HeLa/INS), the control variants correlated well between centers by range of effect; the 
MODY control variants presented the most severe effect, and the type 2 diabetes risk variants medium 
effects (deviation by the p.Ala116Val MODY control variant in one promoter assay). For the exome 
variants, the functional effect also correlated between centers, i.e. less severe effect than the rare type 2 risk 
variant (p.Glu508Lys) (deviation p.Pro291Ser between Centers). Overall, values of all tested variants were 
somewhat lower at one center (Bergen). 
For the subsequent DNA binding assay, only one mutual exome variant was tested at both centers 
(p.Ala174Val), revealing correlating effects between the two centers. The same applied to the two MODY 
variants, although lower values (more severe effect) were detected at one center (Oxford). 
For the protein expression assay, the MODY and type 2 risk variants correlated well between the centers 
(deviation for p.Glu508Lys exhibiting stronger reducing effect by one center (Bergen <0.6 fold versus 
Oxford WT-like). Two (p.Asn62Ser, p.Arg583Gln) of the five exome variants also deviated between the 
two centers (Oxford ~0.6 fold versus Bergen WT-like). 
The nuclear localization assay correlated less between the centers. Two (p.Pro447Leu, p.Ala116Val) of six 
MODY variants, the two type 2 risk variants (p.Ala98Val, p.Glu508Lys), and the two exome variants 
(p.Ala174Val, p.Arg583Gln) did not correlate by range of effect (Bergen by stronger reducing effect 
compared to Oxford). The non-patient related control variant included as the best indicator of strongly 
reduced nuclear localization (DelB) did, however, correlate well between centers. 
Of the four functional assays, it was not unexpected that functional effect between centers correlated best 
for the transactivation and DNA binding assays, whereas the protein expression and nuclear localization 
assays had more variable effect sizes when compared. This latter is most likely due several experimental 






























































































































   








































Figure S5. Functional Studies of Protein Variants (Bergen) 
A and B) Transcriptional activity of HNF-1A protein variants measured by luciferase reporter assay. 
Transcriptional activity was performed in two individual cell lines using two different promoter-linked 
luciferase reporter constructs. A) HeLa cell line using rat albumin promoter and B) INS-1 cell line using 
HNF4AP2 promoter. Cells were transiently transfected with wild-type or variant HNF1A variant plasmids 
together with reporter plasmids pGL3-RA (Firefly Luciferase under rat albumin promoter) or pGL3-
HNF4AP2 (Firefly Luciferase under HNF4AP2 promoter), and pRL-SV40 (Renilla Luciferase as internal 
control). Cells were harvested/lysed 24 h after transfection and Firefly activity recorded after normalizing 
for Renilla activity. HNF-1A variant measurements are given in percentage of wild-type activity (100%). 
Each bar represents the mean of nine readings ± SD; three parallel readings were conducted on each of 3 
experimental days (n = 3). Different colors are used for different group of variants; shared control variants 
are shown in green, type 2 diabetes associated variants in pink and MODY control variants in yellow.  
C) Variant effect on HNF-1A protein expression level. The level of expression of HNF-1A variant proteins 
was assessed relative to wild-type protein level in cells. For this purpose, 20 µl HeLa cell lysates prepared 
for transactivation assay (panel A) was analyzed by SDS-PAGE and immunoblotting using an HNF-1A 
specific antibody. A house-keeping protein (actin) was used as internal control for normalization and bands 
were quantitated using densitometric analysis by Quantity One 1-D software. Each bar represents the level 
of HNF-1A protein expression normalized to wild-type HNF-1A expression level (100%). Different colors 
are used for different group of variants; shared control variants are shown in green, type 2 diabetes 
associated variants in pink and MODY control variants in yellow. 
D) Nuclear localization of HNF-1A variant proteins. The effect of individual HNF1A variants on HNF-1A 
protein localization (nuclear versus cytosolic) was assessed in cells. For this purpose, HeLa cells were 
cultured and transiently transfected with wild-type or HNF1A variant plasmids and sequential cell 
fractionation was performed 24h post-transfection by isolating the nuclear and cytosol fractions from each 
transfected sample. 20 µg total protein from each isolated compartment was analyzed for HNF-1A 
expression by SDS-PAGE and immunoblotting using an HNF-1A specific antibody. HNF-1A variant 
p.delB was included as a positive control for impaired nuclear localization (cytosolic retention).  HNF-1A 
variant nuclear localization measurements are given in percentage of wild-type localization. Each bar 
represents the mean of nuclear localization of HNF-1A protein of two biological replicates in two 
experimental days (n = 2). Different colors are used for different group of variants; shared control variants 
are shown in green, type 2 diabetes associated variants in pink and MODY control variants in yellow. 
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E) DNA binding of HNF-1A protein variants to the rat albumin promoter as studied by EMSA. DNA 
binding ability test was conducted for HNF-1A variants that are either located in DNA binding domain (1-
287 aa) or those that demonstrated transactivation activity < 50%. Electrophoretic mobility shift assay 
(EMSA) was performed to investigate the DNA binding ability of equal amounts of in vitro-synthesized 
HNF-1A proteins to a 32P-radiolabeled rat albumin oligonucleotide containing an HNF-1A binding site. A 
coupled in vitro transcription and translation system (TNT) was used for expression of HNF-1A proteins. 
DNA-protein bound complexes were analyzed by DNA retardation gel (6%) electrophoresis followed by 
autoradiography. Level of DNA binding was obtained by quantification of the intensity of HNF-1A protein-
oligonucleotide complexes. Measurements are given in percentage of wild-type binding activity (100%). 
Two HNF1A-MODY3 variants were used as control for low binding (yellow) and shared control variants 









































Figure S6. Functional Studies of Protein Variants (Oxford) 
A and B) Transcriptional activity of HNF-1A protein variants measured by luciferase reporter assay. 
Transcriptional activity was performed in two individual cell lines using two different promoter-linked 
luciferase reporter constructs. A) HeLa cell line using rat albumin promoter and B) INS-1 cell line using 
HNF4A P2 promoter. Cells were transiently transfected with wild-type or variant HNF1A variant plasmids 
together with reporter plasmids pGL3-RA (Firefly Luciferase under rat albumin promoter) or pGL3-
HNF4A P2 (Firefly Luciferase under HNF4A P2 promoter), and pRL-SV40 (Renilla Luciferase as internal 
control). Cells were harvested/lysed 24 h after transfection and Firefly activity recorded after normalizing 
for Renilla activity. HNF-1A variant measurements are given in percentage of wild-type activity (100%). 
Each bar represents the mean of nine readings ± SD; three parallel readings were conducted on each of 
three experimental days (n = 3). Different colors are used for different group of variants; shared control 
variants are shown in green, type 2 diabetes associated variants in pink and MODY control variants in 
yellow.  
C) Variant effect on HNF-1A protein expression level. The level of expression of HNF-1A variant proteins 
was assessed relative to wild-type protein level in cells. For this purpose, HeLa cells were cultured and 
transiently transfected with wild-type or HNF1A variant plasmids. Cells were harvested at 24 hrs and 
aliquoted prior to lysing for the protein expression levels and EMSA or nuclear localization. 10 µg of HeLa 
cell lysates prepared for transactivation assay (Figure A) was analyzed by SDS-PAGE and immunobloting 
using an HNF-1A specific antibody. A house-keeping protein (B-tubulin) was used as internal control for 
normalization of levels of tubulin versus HNF-1A specific bands., using densitometric analysis by Image 
Lab software (Bio-Rad). Each bar represents the level of HNF-1A protein expression normalized to wild-
type HNF-1A expression level (100%). Different colors are used for different groups of variants; shared 
control variants are shown in green, type 2 diabetes associated variants in pink and MODY control variants 
in yellow. 
D) Nuclear localization of HNF-1A variant proteins. The effect of individual HNF1A variants on HNF-1A 
protein localization (nuclear versus cytosolic) was assessed in cells. For this purpose, an aliquot of the HeLa 
cells that had been transfected and harvested at 24hr were lysed to isolate the nuclear and cytosol fraction. 
20 µg total protein from each isolated compartment was analyzed for HNF-1A expression by SDS-PAGE 
and immunobloting using an HNF-1A specific antibody. HNF-1A variant p.delB was included as a positive 
control for impaired nuclear localization (cytosolic retention). HNF-1A variant nuclear localization 





localization of HNF-1A protein of two biological replicates in two experimental days (n = 2). Different 
colors are used for different groups of variants; shared control variants are shown in green, type 2 diabetes 
associated variants in pink and MODY control variants in yellow. 
E) DNA binding of HNF-1A protein variants to the rat albumin promoter as studied by EMSA. DNA 
binding ability test was conducted for HNF1A variants that are either located in DNA binding domain (1-
287 aa) or those that demonstrated transactivation activity < 50%. Electrophoretic mobility shift assay 
(EMSA) was performed using an aliquot of the lysed HeLa cells used for the protein expression levels. The 
HNF-1a wild-type or variant protein was bound to a fluorescently labelled probe and then separated using 
a TBE polyacrylamide gel. An HNF-1a antibody was used to generate a super-shift with an aliquot of the 
wild-type protein, prior to the probe binding. Measurements are given as percentage of wild-type binding 
activity (100%). Different colors are used for different groups of variants; shared control variants are shown 

























Figure S7. Clustering Alignment of HNF1A Missense Variants Shared Between Both Centres at 
Oxford (dend1and Bergen (dend2). Entanglement (quality of alignment score score from 1 to 0 where 
lower values = good alignment quality) = 0.055. Dashed lines highlight nodes which contain a combination 
of alleles not present in the other tree (thickness corresponds to height). The connecting lines highlight 
subgroups and/or cluster members that are present in both dendrograms. Rotational properties maintained 















Table S1. Exome-Detected HNF1A Missense Alleles Selected for Functional Follow-Up (n = 73) 
(Excel file) 
HNF1A reference sequence = NM_000545.6. Colour coding of first three columns (Variant and CDS 
position NM_0005454): blue = Oxford variant set; red = Bergen variant set; gray = variants shared and 
characterised by both research groups at Oxford and Bergen. Green highlights variants identified with a 
prevalence greater than 0. 
 
 




Table S3. Scores for Tissue Specific Isoform Expression and Functional Domain  
Isoform  Functional Domain  
 
Pancreatic beta-cell isoforms 
HNF1A(A): exons 1-6  
UniProtKB Protein isoform identifier P208231-3  
 
HNF1A(B): exons 1-7  
UniProtKB Protein isoform identifier P208231-2 
 
Hepatic isoform (full length gene) 
HNF1A(C): exons 1-10 
NCBI Reference Sequence: NM_000545.8 





Variants in HNF1A(A) and HNF1A(B) = [(no. of exons in 
predominant beta-cell isoforms) ÷ 10 (no. of exons in full 
length HNF1A)] × 100 = 70% 
 
Variants exclusively present in HNF1A(C) = [(no. of 
additional exons present exclusively in predominant liver 




HNF-1A functional domains 
Dimerization   =   32 amino acids 
Undefined   =   66 amino acids 
DNA binding   =   187 amino acids 











[no. of amino acids of domain in which allele is expressed 
÷ amino acid length of HNF-1a] × 100  
 
 
Dimerization     =     4.9%  
Undefined     =     10.45%  
DNA binding     =     29.6%  














Table S4. Features of HNF1A Allele Carriers Documented in UK Registry 
 
 
GAD, ICA, IA2, ZnT8 = islet autoantibodies; UCPCR = urinary C-peptide creatinine ratio; OHA = oral 




Table S5. Features of HNF1A Allele Carriers Documented in Norwegian Registry 
 
GAD, IA2, ZnT8 = islet autoantibodies; OHA = oral hypoglycemic      agent; BMI = body mass index; 








Table S6. Clinical Features Associated with Functionally-Clinically Discordant HNF1A Alleles in 
UK Registry 
(Excel file) 
Clinical features and additional information available on each of the listed alleles from the UK MODY 
diagnostic registry. With the exception of p.R131Q (n = 4 documented cases; information displayed as 
range across the four), details are associated with a single case. Abbreviations: NGS = next generation 




Table S7. Clinical Features Associated with Functionally-Clinically Discordant HNF1A Alleles in 
Norwegian Registry 
(Excel file) 
Clinical features and additional information available on each of the listed alleles from the Norway 
MODY diagnostic registry. Abbreviations: NGS = next generation sequencing; dx = diagnosis; SU = 
sulfonylurea; FH = family history; BMI = body mass index; HbA1c = glycated hemoglobin 
